Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that its first ...

These new results demonstrate the ability of LX-101 to effectively target the underlying processes that drive TED pathogenesis ... 101 in oncology and autoimmune indications, including thyroid eye ...

Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

for the treatment of thyroid eye disease (TED). As China's first and the world's second approved IGF-1R antibody drug, SYCUME® has ended a 70-year drought of no new treatment option for TED in China.

Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Background: Dysthyroid optic neuropathy (DON), the most severe complication of thyroid eye disease (TED), has unclear mechanisms ... related molecules and immune cell infiltration in its pathogenesis.

What are styes and chalazia? Penn Medicine. Thyroid eye disease (Graves' disease). National Eye Institute. Uveitis. Kalambay J, Ghazanfar H, Martes Pena K A, et al. Pathogenesis of drug induced ...

Her thyroid ... Graves’ disease – 21.2%; Addison’s disease and type 1 diabetes – 10.9%; Addison’s disease, chronic thyroiditis, and type 1 diabetes – 9.6%; Addison’s disease, Graves’ disease and type ...